Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Novo Nordisk shares are experiencing a significant decline amidst intensified investor concerns over its competitiveness in ...

Amy Schumer has opened up about her current health journey, revealing that she’s seeing strong results using the weight loss ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

GEMMA Collins has today revealed the horrifyingly cruel nickname she was called before going on fat jabs. The TV favourite, ...

Schumer said she was having success on Mounjaro after previously being unable to "handle" Ozempic's side effects.

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

JM Financial is bullish on Mounjaro's success in India, citing its price advantage, higher efficiency and the country's large ...

The immense demand for Ozempic and Wegovy has also strained supply ... deeming the trial a success. While competitors are developing GLP-1 agonists, the trials for pharmaceutical drugs are ...

Equinox's GLP-1 protocol is considered a framework for people taking the drugs, one that addresses workout intensity, ...

A total of 29 new blockbuster-in-waiting drugs entered the late-stage pipeline in 2024, a jump from the previous year’s 19.

A woman is clapping back at critics after receiving body-shaming comments despite having success in her weight loss journey.